Oncogenic mutations weaken the interactions that stabilize the p110α‐p85α heterodimer in phosphatidylinositol 3‐kinase α

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The FEBS Journal

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/febs.13365PMID 26122737PMCID PMC4573839
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Allostery without a conformational change? Revisiting the paradigm.

  2015cited by this paper
• Targeting PI3 kinase in cancer.

  2015cited by this paper
• A Unified View of “How Allostery Works”

  2014cited by this paper
• Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.

  2014cited by this paper
• Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant

  2014cited by this paper
• The ensemble nature of allostery

  2014cited by this paper
• Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects

  2014cited by this paper
• Targeting PI3K/Akt/mTOR Signaling in Cancer

  2014cited by this paper
• Structural basis of nSH2 regulation and lipid binding in PI3Kα

  2014cited by this paper
• Computational Modeling of Allosteric Regulation in the Hsp90 Chaperones: A Statistical Ensemble Analysis of Protein Structure Networks and Allosteric Communications

  2014cited by this paper
• Targeting PI3Kδ

  2013cited by this paper
• Impact of mutations on the allosteric conformational equilibrium.

  2013cited by this paper
• Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

  2013cited by this paper
• Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA)

  2012cited by this paper
• Protein dynamics and conformational selection in bidirectional signal transduction

  2012cited by this paper
• Conformational Sampling of Maltose-transporter Components in Cartesian Collective Variables is Governed by the Low-frequency Normal Modes.

  2012cited by this paper
• Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms.

  2012cited by this paper
• Using enhanced sampling and structural restraints to refine atomic structures into low-resolution electron microscopy maps.

  2012cited by this paper
• Dynamics of the Phosphoinositide 3-Kinase p110δ Interaction with p85α and Membranes Reveals Aspects of Regulation Distinct from p110α

  2011cited by this paper
• Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

  2011cited by this paper
• Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases

  2011cited by this paper
• Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism

  2011cited by this paper
• A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

  2011cited by this paper
• Isoform-Selective Inhibition of Phosphoinositide 3-Kinase: Identification of a New Region of Nonconserved Amino Acids Critical for p110α Inhibition

  2011cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

  2010cited by this paper
• Functional differences between two classes of oncogenic mutation in the PIK3CA gene.

  2009cited by this paper
• CHARMM: The biomolecular simulation program

  2009cited by this paper
• A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane

  2009cited by this paper
• Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants

  2009cited by this paper
• Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms

  2009cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Mechanism of signal propagation upon retinal isomerization: insights from molecular dynamics simulations of rhodopsin restrained by normal modes.

  2008cited by this paper
• Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

  2008cited by this paper
• Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

  2008cited by this paper
• Allostery: absence of a change in shape does not imply that allostery is not at play.

  2008cited by this paper
• Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

  2008cited by this paper
• Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

  2007cited by this paper
• Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers

  2007cited by this paper
• The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

  2007cited by this paper
• The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

  2007cited by this paper
• Rare cancer-specific mutations in PIK3CA show gain of function

  2007cited by this paper
• Low-frequency normal modes that describe allosteric transitions in biological nanomachines are robust to sequence variations

  2006cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• Dynamically driven protein allostery

  2006cited by this paper
• Scalable molecular dynamics with NAMD

  2005cited by this paper
• Coarse-grained normal mode analysis in structural biology.

  2005cited by this paper
• Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Escherichia coli adenylate kinase dynamics: Comparison of elastic network model modes with mode‐coupling 15N‐NMR relaxation data

  2004cited by this paper
• Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

  2004cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• Oncogenic Mutations of PIK3CA in Human Cancers

  2004cited by this paper
• Oncogenic mutations of PIK3CA in human cancers.

  2004cited by this paper
• Modeller: generation and refinement of homology-based protein structure models.

  2003cited by this paper
• Quantifying the accessible surface area of protein residues in their local environment.

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

  2001cited by this paper
• Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer

  2001cited by this paper
• Conformational change of proteins arising from normal mode calculations.

  2001cited by this paper
• All-atom empirical potential for molecular modeling and dynamics studies of proteins.

  1998cited by this paper
• Correlation between native-state hydrogen exchange and cooperative residue fluctuations from a simple model.

  1998cited by this paper
• Is stimulation of class-1 phosphatidylinositol 3-kinase activity by insulin sufficient to activate pathways involved in glucose metabolism.

  1997cited by this paper
• Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems

  1993cited by this paper
• Allostery without conformational change

  1984cited by this paper
• CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

  1983cited by this paper
• Somatic mutations

  1978cited by this paper

• Decoding the functional impact of the cancer genome through protein–protein interactions

  2025cites this paper
• The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions

  2025cites this paper
• Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

  2025cites this paper
• A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors

  2024cites this paper
• Survey for Activating Oncogenic Mutation Variants in Metazoan Germline Genes

  2024cites this paper
• ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding

  2024cites this paper
• Predator: Predicting the Impact of Cancer Somatic Mutations on Protein-Protein Interactions

  2023cites this paper
• Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha

  2023cites this paper
• Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms

  2023cites this paper
• Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).

  2023cites this paper
• The orchestrated signaling by PI3Kα and PTEN at the membrane interface

  2022cites this paper
• Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα

  2022cites this paper
• Class I PI3K Biology.

  2022cites this paper
• High incidence of PI3K pathway gene mutations in South Indian cervical cancers.

  2022cites this paper
• Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

  2021cites this paper
• Allicin protects against myocardial I/R by accelerating angiogenesis via the miR-19a-3p/PI3K/AKT axis

  2021cites this paper
• RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

  2021cites this paper
• mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)

  2020cites this paper
• Deciphering the molecular mechanism of FLT3 resistance mutations.

  2020cites this paper
• Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.

  2020influential citation
• Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2020cites this paper
• Achieving High Levels of Selectivity for Kinase Inhibitors

  2020cites this paper
• Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease

  2019cites this paper
• Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase α Inhibitors

  2019cites this paper
• Computational Structural Biology: Successes, Future Directions, and Challenges

  2019cites this paper
• Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight

  2019cites this paper
• The mechanism of PI3Kα activation at the atomic level† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc04498h

  2019cites this paper
• Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

  2018cites this paper
• Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations

  2018cites this paper
• Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation

  2018cites this paper
• The impact of heterogeneity in phosphoinositide 3-kinase pathway in human cancer and possible therapeutic treatments.

  2017cites this paper
• Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

  2017cites this paper
• Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans.

  2017cites this paper
• PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.

  2017cites this paper
• Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β

  2017cites this paper
• Molecular Dynamics Simulations to Investigate the Binding Mode of the Natural Product Liphagal with Phosphoinositide 3-Kinase α

  2016cites this paper
• Na+ coordination at the Na2 site of the Na+/I− symporter

  2016cites this paper
• Evading inhibitory constraints – destabilizing p110α/p85α interactions

  2015cites this paper